IP Library › Granted Patent US 7,303,765
Granted Patent B2
US 7,303,765 · App. 11/041,272 · Granted Dec 4, 2007

Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,303,765
App. No.
11/041,272
Granted
Dec 4, 2007
Kind
B2
Abstract

L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently formulated with oil-based materials.

Claims (11)

1. A composition, consisting of L-carnitine particles, having a particle size such that the particles substantially pass through a 100 USBS mesh sieve blended with a silica having an overall surface area of from 190 to 475 square meters per gram and a tapped density of from 80 to 275 grams per liter wherein L-carnitine is present in an amount of 10% to 99% by weight, based on the total weight of the composition.

2. The composition of claim 1 , which is selected from the group consisting of L-carnitine, salts of L-carnitine, alkanoyl L-carnitines, and salts of alkanoyl L-carnitine.

3. The composition of claim 1 , which is selected from the group consisting of L-carnitine chloride, L-carnitine bromide, L-carnitine orotate, L-carnitine acid aspartate, L-carnitine acid phosphate, L-carnitine fumarate, L-carnitine lactate, L-carnitine maleate, L-carnitine acid maleate, L-carnitine acid oxalate, L-carnitine acid sulfate, L-carnitine glucose phosphate, L-carnitine tartrate, L-carnitine acid tartrate, L-carnitine iodate, L-carnitine aspartate, L-carnitine citrate, L-carnitine acid citrate, L-carnitine acid fumarate, L-carnitine glycerophosphate, L-carnitine mucate, L-carnitine orotate, L-carnitine oxalate, L-carnitine sulfate, L-carnitine trichloroacetate, L-carnitine trifluoroacetate, L-carnitine methanesulfonate, L-carnitine pamoate, L-carnitine acid pamoate, C 2-8 alkanoyl L-carnitines, C 2-8 alkanoyl L-carnitine chloride, C 2-8 alkanoyl L-carnitine bromide, C 2-8 alkanoyl L-carnitine orotate, C 2-8 alkanoyl L-carnitine acid aspartate, C 2-8 alkanoyl L-carnitine acid phosphate, C 2-8 alkanoyl L-carnitine fumarate, C 2-8 alkanoyl L-carnitine lactate, C 2-8 alkanoyl L-carnitine maleate, C 2-8 alkanoyl L-carnitine acid maleate, C 2-8 alkanoyl L-carnitine acid oxalate, C 2-8 alkanoyl L-carnitine acid sulfate, C 2-8 alkanoyl L-carnitine glucose phosphate, C 2-8 alkanoyl L-carnitine tartrate, C 2-8 alkanoyl L-carnitine acid tartrate, C 2-8 alkanoyl L-carnitine iodate, C 2-8 alkanoyl L-carnitine aspartate, C 2-8 alkanoyl L-carnitine citrate, C 2-8 alkanoyl L-carnitine acid citrate, C 2-8 alkanoyl L-carnitine acid fumarate, C 2-8 alkanoyl L-carnitine glycerophosphate, C 2-8 alkanoyl L-carnitine mucate, C 2-8 alkanoyl L-carnitine orotate, C 2-8 alkanoyl L-carnitine oxalate, C 2-8 alkanoyl L-carnitine sulfate, C 2-8 alkanoyl L-carnitine trichloroacetate, C 2-8 alkanoyl L-carnitine trifluoroacetate, C 2-8 alkanoyl L-carnitine methanesulfonate, C 2-8 alkanoyl L-carnitine pamoate, and C 2-8 alkanoyl L-carnitine acid pamoate.

4. A method of preparing a composition, consisting of (1) subjecting L-carnitine having a particle size such that it does not pass through a 100 USBS mesh sieve to size reduction, to obtain size-reduced L-carnitine; (2) subjecting said size-reduced L-carnitine to sieving through a 100 USBS mesh sieve (3) selecting the portion which passes through said 100 USBS mesh sieve and blending said portion with a silica having an overall surface area of from 190 to 475 square meters per gram and a tapped density of from 80 to 275 grams per liter wherein L-carnitine is present in amount of 10% to 99% by weight, based on the total weight of the composition.

5. The method of claim 4 , wherein said L-carnitine is selected from the group consisting of L-carnitine, salts of L-carnitine, alkanoyl L-carnitines, and salts of alkanoyl L-carnitine.

6. The method of claim 4 , wherein said L-carnitine is selected from the group consisting of L-carnitine chloride, L-carnitine bromide, L-carnitine orotate, L-carnitine acid aspartate, L-carnitine acid phosphate, L-carnitine fumarate, L-carnitine lactate, L-carnitine maleate, L-carnitine acid maleate, L-carnitine acid oxalate, L-carnitine acid sulfate, L-carnitine glucose phosphate, L-carnitine tartrate, L-carnitine acid tartrate, L-carnitine iodate, L-carnitine aspartate, L-carnitine citrate, L-carnitine acid citrate, L-carnitine acid fumarate, L-carnitine glycerophosphate, L-carnitine mucate, L-carnitine orotate, L-carnitine oxalate, L-carnitine sulfate, L-carnitine trichloroacetate, L-carnitine trifluoroacetate, L-carnitine methanesulfonate, L-carnitine pamoate, L-carnitine acid pamoate, C 2-8 alkanoyl L-carnitines, C 2-8 alkanoyl L-carnitine chloride, C 2-8 alkanoyl L-carnitine bromide, C 2-8 alkanoyl L-carnitine orotate, C 2-8 alkanoyl L-carnitine acid aspartate, C 2-8 alkanoyl L-carnitine acid phosphate, C 2-8 alkanoyl L-carnitine fumarate, C 2-8 alkanoyl L-carnitine lactate, C 2-8 alkanoyl L-carnitine maleate, C 2-8 alkanoyl L-carnitine acid maleate, C 2-8 alkanoyl L-carnitine acid oxalate, C 2-8 alkanoyl L-carnitine acid sulfate, C 2-8 alkanoyl L-carnitine glucose phosphate, C 2-8 alkanoyl L-carnitine tartrate, C 2-8 alkanoyl L-carnitine acid tartrate, C 2-8 alkanoyl L-carnitine iodate, C 2-8 alkanoyl L-carnitine aspartate, C 2-8 alkanoyl L-carnitine citrate, C 2-8 alkanoyl L-carnitine acid citrate, C 2-8 alkanoyl L-carnitine acid fumarate, C 2-8 alkanoyl L-carnitine glycerophosphate, C 2-8 alkanoyl L-carnitine mucate, C 2-8 alkanoyl L-carnitine orotate, C 2-8 alkanoyl L-carnitine oxalate, C 2-8 alkanoyl L-carnitine sulfate, C 2-8 alkanoyl L-carnitine trichloroacetate, C 2-8 alkanoyl L-carnitine trifluoroacetate, C 2-8 alkanoyl L-carnitine methanesulfonate, C 2-8 alkanoyl L-carnitine pamoate, and C 2-8 alkanoyl L-carnitine acid pamoate.

7. The composition of claim 1 , which is suitable for oral ingestion.

8. The composition of claim 1 , wherein the L-carnitine particles have a particle size such that they substantially pass through a 150 USBS mesh sieve.

9. The composition of claim 1 , wherein the L-carnitine particles have a particle size such that they substantially pass through a 200 USBS mesh sieve.

10. The L-carnitine containing composition of claim 1 wherein the L-carnitine is L-carnitine fumarate.

11. A composition, consisting of L-carnitine particles, having a particle size such that the particles substantially pass through a 100 USBS mesh sieve blended with a silica having an overall surface area of from 190 to 475 square meters per gram and a tapped density of from 80 to 275 grams per liter, and a member of the group consisting of hydroxycitric acid, Co-enzyme Q10, chromium picolinate, gamma linolenic acid, resveratrol, omega 3 acids, antioxidants, and vitamins, wherein L-carnitine is present in an amount of 10% to 99% by weight, based on the total weight of the composition.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 15, 2019
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 050727/0652 →
MERGER Recorded Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 044760/0906 →